Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BP101 in healthy women
NCT03102489Phase 1Completed
- Start
- Feb 2017
- Primary completion
- Jun 2017
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in hypoactive sexual desire disorder (HSDD) comparing BP101 with Placebo (2 arms). Primary endpoint: Incidence of treatment-emergent Adverse Events at 6 weeks. Started Feb 2017; status: completed.
02
Drugs
BP101
03
Conditions
hypoactive sexual desire disorder (HSDD)
Beyond the preview
Go deeper on NCT03102489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03102489.